{"id":"NCT02353871","sponsor":"Ipsen","briefTitle":"Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines","officialTitle":"A Phase III, Double Blind, Randomised, Placebo Controlled Study To Assess The Efficacy And Safety Of A Single Treatment Of Clostridium Botulinum Toxin Type A To Improve The Appearance Of Moderate To Severe Glabellar Lines","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01","primaryCompletion":"2015-04","completion":"2015-08","firstPosted":"2015-02-03","resultsPosted":"2017-10-02","lastUpdate":"2022-09-28"},"enrollment":185,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Moderate to Severe Glabellar Lines"],"interventions":[{"type":"BIOLOGICAL","name":"Botulinum toxin type A","otherNames":["BTX-A-HAC NG"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"BTX-A-HAC NG","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to demonstrate the safety and the efficacy of a single treatment of an injectable liquid form of Clostridium botulinum toxin type A haemagglutinin complex (BTX-A-HAC; hereafter referred to as BTX-A-HAC Next Generation (BTX-A-HAC NG)), used for the improvement in the appearance of moderate to severe glabellar lines (the lines between the eyebrows).","primaryOutcome":{"measure":"The Proportion of Responders at Day 29 in the ILA of Glabellar Lines at Maximum Frown.","timeFrame":"Day 29","effectByArm":[{"arm":"BTX-A-HAC NG Solution (50 U)","deltaMin":88.3,"sd":null},{"arm":"Placebo","deltaMin":1.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":9,"countries":["France","Germany"]},"refs":{"pmids":["36206385"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":125},"commonTop":["Headache","Nasopharyngitis","Injection site pain","Influenza","Tonsillitis"]}}